Can You Buy Peptides Without a Prescription? What That Vial Actually Is

The Federal Food, Drug, and Cosmetic Act defines a prescription drug as one that, "because of its toxicity or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary to its use, is not safe for use except under the supervision of a practitioner licensed by law to administer such drug." It may be dispensed only on a written or oral prescription, or a refill of one, and "the act of dispensing a drug contrary to the provisions of this paragraph shall be deemed to be an act which results in the drug being misbranded while held for sale." An injectable peptide meets the "method of its use" test on its face, and the violation lands on the person dispensing, not the person receiving.

The "research use only" wording tracks a specific regulation, 21 CFR 201.125, which exempts a drug from carrying adequate directions for use when it is "shipped or sold to, or in the possession of, persons regularly and lawfully engaged in instruction in pharmacy, chemistry, or medicine not involving clinical use, or engaged in law enforcement, or in research not involving clinical use, or in chemical analysis, or physical testing, and is to be used only for such instruction, law enforcement, research, analysis, or testing." The exemption is for research not involving clinical use, by persons regularly and lawfully engaged in it. A consumer injecting the contents into their own abdomen is the clinical use the regulation expressly excludes.

The second regulation, 21 CFR 201.128, says a product's intended use is determined by the "objective intent" of the people selling it, which "may, for example, be shown by labeling claims, advertising matter, or oral or written statements by such persons or their representatives," and "by circumstances in which the article is, with the knowledge of such persons or their representatives, offered or used for a purpose for which it is neither labeled nor advertised." A site that discusses dosing schedules, injection technique and results in people has, under this regulation, stated an intended use for humans, whatever the vial says. The disclaimer pulls the product back under the research exemption; the marketing pushes it out again.

The FDA's current statement on unapproved GLP-1 drugs says the agency "has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled 'for research purposes' or 'not for human consumption,'" noting the products were marketed directly to consumers with dosing instructions. The same page states that salt forms such as semaglutide sodium and semaglutide acetate "are different active ingredients than are used in the approved drugs," and gives the agency's advice in one sentence: "Patients should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy." The word "falsely" is the agency's own.

None of these provisions is written against the individual buyer; misbranding attaches to the dispenser and intended use to the seller. What a buyer carries is the absence of every protection the prescription system exists to provide.

Section 503A exempts a compounded drug from three requirements, new-drug approval, current good manufacturing practice and labeling with adequate directions for use, provided a set of conditions is met. The product must be "compounded for an identified individual patient based on the receipt of a valid prescription order," by "a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician." The FDA's summary is one sentence: "One of these conditions is that the drugs must be compounded based on the receipt of valid patient-specific prescriptions." The prescription is not paperwork bolted onto the sale. It is the legal event that makes the sale possible.

The statute also restricts what a 503A pharmacy may compound from. The bulk drug substance must comply with a United States Pharmacopeia or National Formulary monograph, be a component of an FDA-approved drug, or "appear on a list developed by the Secretary," the 503A bulks list. It must also come from an FDA-registered establishment with a valid certificate of analysis. This is why a legitimate provider sometimes cannot offer a molecule a research site will happily ship: the pharmacy is bound by the list, the research site by nothing.

The exemption is from FDA pre-market approval, federal manufacturing regulations and full-directions labeling. It is not an exemption from state pharmacy law, from licensure of the pharmacy and pharmacist, from sterile-compounding standards, or from the prescription itself. The FDA's compounding Q&A is unambiguous on the approval point: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." That applies to the prescription version of every product in the table above, and Pepti says so on each product page. (503B outsourcing facilities are a separate category, subject to CGMP and able to ship to provider orders; the peptides here are prepared under 503A, patient by patient.)

Section 503A requires a state-licensed pharmacy and a licensed prescriber, so the details are set state by state: which practitioners may prescribe, whether a telehealth visit satisfies the prescribing relationship, what a pharmacy needs to ship into a given state, and what the state board of pharmacy requires of a compounder. Those rules differ and they change, which is why a provider's availability is not identical in every state. What holds everywhere is that a valid prescription from a practitioner licensed in your state, filled by a pharmacy licensed to ship to your state, is the legal route; a legitimate provider can tell you which pharmacy is filling yours and under which license.

The FDA sorts substances nominated for the 503A bulks list into three categories. Category 1 substances "may be eligible for inclusion on the 503A bulks list, were nominated with sufficient supporting information for FDA to evaluate them, and do not appear on any other list," and the agency has said it does not intend to act against compounding with them while evaluation proceeds. For Category 2, "FDA has identified significant safety risks relating to the use of these substances in compounding pending further evaluation." Category 3 substances "were nominated with insufficient supporting information for FDA to evaluate them." The current list is dated 14 May 2026.

In 2023 the FDA placed a group of peptides, including BPC-157 and TB-500, in Category 2. On 15 April 2026 the agency announced it was removing twelve peptides from Category 2 and would instead take them to its Pharmacy Compounding Advisory Committee: seven at a meeting on 23–24 July 2026 and five more before the end of February 2027. Removal from Category 2 did not by itself place them in Category 1 or on the bulks list; it moved them out of the "significant safety risk" designation and into formal evaluation. On the 14 May 2026 list, Category 2 no longer contains BPC-157, TB-500 or any of the other eleven.

The meeting discussed BPC-157, KPV, TB-500 and MOTS-c on the first day and DSIP, Semax and epitalon on the second. The committee voted 8–6 to recommend BPC-157, KPV and TB-500 for the 503A bulks list, with favorable votes on several others. An advisory vote is not a listing. The FDA's own briefing document states that the agency "will not issue a final determination on the issues at hand until input from the advisory committee process has been considered and all reviews have been finalized." Listing is done by rulemaking, which follows the vote.

Both are in that group: no longer in Category 2, recommended by the advisory committee in July 2026, awaiting the FDA's final determination. Neither is FDA approved, neither has a USP monograph, and neither is a component of an approved drug; the FDA's BPC-157 briefing document says so in as many words. Current status is on the BPC-157 and TB-500 pages and in the BPC-157 reference.

The 14 May 2026 update is specifically about GHK-Cu. The FDA added "GHK-Cu (except for injectable routes of administration)" back to Category 1 after a nominator clarified it was withdrawing only its injectable nomination, and the agency intends to consult the advisory committee before the end of February 2027 on GHK-Cu's potential inclusion on the list. The GHK-Cu page carries the current position.

Nicotinamide adenine dinucleotide appears in Category 1 on the current list, alongside methylcobalamin, glutathione and acetyl-L-carnitine. NAD+ injection remains a compounded, non-approved preparation.

Semaglutide is a different case. It is the active ingredient of FDA-approved products, so a 503A pharmacy may compound with it under the "component of an approved drug" prong rather than via the bulks list. That is exactly why the FDA's warning about "semaglutide sodium" matters: a salt form is a different active ingredient and is not a component of the approved drug. The compounded semaglutide Pepti prescribes is still not an FDA-approved product. The CJC-1295 / Ipamorelin and sermorelin pages likewise carry their own current regulatory position; a research vendor's page does not.

Whatever the FDA finally lists, none of it makes any of these peptides an approved drug and none of it creates a lawful over-the-counter route. A listing is permission for a licensed pharmacy to compound pursuant to a prescription.

You complete a medical intake: history, current medications, allergies, what you are treating and what you have tried. This is the document that lets a physician rule things out. Pepti's starts at the free assessment.

A physician licensed in your state reviews the intake. They may decline, ask for more information, or ask for bloodwork first; at-home blood testing exists for that. A consultation does not guarantee a prescription, and a provider that never declines anyone is not reviewing anything.

If the physician prescribes, the prescription, for you by name, goes to a state-licensed pharmacy operating under section 503A, which sources a bulk substance that meets the statute, prepares it under sterile-compounding standards, and labels it with your name, the concentration and your directions. This is the step the research site replaces with a bag of powder.

The vial ships refrigerated, in insulated packaging, with directions printed on the label in milliliters and syringe units and beyond-use dating printed on it. What you draw is what the label says.

Treatment is long-term and runs on 28-day refills, one vial per fill. The prescriber stays reachable for dose questions and side effects, and refills are reviewed rather than automatic. The fuller description is in where to get prescription peptides online.

Four questions, answered without hesitation: who the prescriber is and where they are licensed; which pharmacy fills the prescription and under which license; what is in the vial, printed on the label; and what testing stands behind it (/quality/lab-results). A seller that cannot answer the first two is not a pharmacy, whatever its checkout page looks like.

BPC-157's evidence base is animal and cell work: a 2006 paper in the Journal of Orthopaedic Research on Achilles tendon detachment in rats, a 2014 paper in Molecules on growth hormone receptor expression in cultured tendon fibroblasts, and the gastrointestinal literature reviewed in Current Pharmaceutical Design in 2011 and 2018. There are no randomized controlled trials of BPC-157 in humans for tendon or soft-tissue injury. TB-500 is a fragment of thymosin beta-4, and the human trials on file are of the parent protein: a randomized, placebo-controlled dose study of intravenous thymosin beta-4 in healthy volunteers in the Annals of the New York Academy of Sciences in 2010, and a phase 2 randomized trial in severe dry eye in Cornea in 2015. The BPC-157 + TB-500 preparation exists because prescribers use the two together; it does not change what has been shown for either.

GHK-Cu has the longest human record of the repair peptides, but for the topical route: a 1994 paper in Wound Repair and Regeneration in patients with diabetic ulcers treated topically, and a 2006 paper in Archives of Facial Plastic Surgery after laser resurfacing. The fibroblast collagen work dates to FEBS Letters in 1988. There are no randomized human trials of injectable GHK-Cu, which is the route in question here.

These have real human pharmacology. A 2006 study in the Journal of Clinical Endocrinology and Metabolism described prolonged growth hormone and IGF-1 secretion after CJC-1295 in healthy adults. Ipamorelin's selectivity was characterized in the European Journal of Endocrinology in 1998, and a randomized, controlled proof-of-concept study in postoperative ileus appeared in the International Journal of Colorectal Disease in 2014. Sermorelin was studied in older men in the Journal of Clinical Endocrinology and Metabolism in 1992 and in a controlled trial of cognitive function in older adults in Archives of Neurology in 2012. What these trials establish is the hormonal response, not the body-composition endpoints that sell these peptides online.

The randomized human trials in the NAD+ literature are of oral precursors rather than injected NAD+ itself: nicotinamide riboside in healthy middle-aged and older adults in Nature Communications in 2018, and nicotinamide mononucleotide in prediabetic women in Science in 2021 and in healthy middle-aged adults in GeroScience in 2023. Injected NAD+ has physician experience behind it, not trial endpoints of its own, and the NAD+ page says so.

Semaglutide is the exception. STEP 1 in the New England Journal of Medicine in 2021 was a randomized, placebo-controlled trial of once-weekly semaglutide in adults with overweight or obesity; SELECT in the same journal in 2023 was a cardiovascular-outcomes trial in obesity without diabetes. Those trials were of the approved products. A compounded semaglutide prescription carries the same active ingredient; a vial of "semaglutide sodium" from a research site does not, by the FDA's own statement.

So the grey market does not fail on the science of the molecule. It fails on everything around the molecule: who decided you should take it, who made it, under what conditions, at what strength, and who answers when something goes wrong. The prescription version is not FDA approved either. It is accountable, which is a different and more achievable claim.